| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Division of Hematology/Oncology, Beth Israel Deaconess Medical Center; 2 Dana-Farber/Harvard Cancer Institute; 3 Brigham and Women's Hospital, Harvard Medical School; 4 Dana-Farber/Harvard Cancer Central Renal Cancer Program, Boston, MA; and Departments of 5 Microbiology and 6 Molecular Genetics, Irvine College of Medicine, University of California, Irvine, California
Requests for reprints: Michael B. Atkins, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-667-1930; Fax: 617-975-8030; E-mail: Matkins{at}bidmc.harvard.edu.
Purpose: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy.
Experimental Design: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome.
Results: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2–based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36%), 31 (47%), and 11 (17%) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62%) had high CAIX expression. Twenty-one of 27 (78%) responding patients had high CAIX expressing tumors compared with 20 of 39 (51%) nonresponders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96%) responders compared with 18 of 39 (46%) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01).
Conclusions: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2–based therapy and may enhance prognostic information obtained from pathology specimens.
Key Words: Renal cancer • Interleukin 2 • CAIX expression • histologic features
This article has been cited by other articles:
|
|
 |
|
  A. J. Pantuck, T. Klatte, D. Seligson, M. Atkins, and A. Belldegrun Carbonic Anhydrase IX As a Predictive Biomarker for Clear Cell Renal Cell Carcinoma J. Clin. Oncol., June 20, 2008; 26(18): 3105 - 3107. [Full Text] [PDF]
|
|
|
|
|
|
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon In Reply J. Clin. Oncol., June 20, 2008; 26(18): 3107 - 3109. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Signoretti, G. Bratslavsky, F. M. Waldman, V. E. Reuter, J. Haaga, M. Merino, G. V. Thomas, M. R. Pins, T. Libermann, J. Gillespie, et al. Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions Clin. Cancer Res., June 15, 2008; 14(12): 3699 - 3705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Michaelson, O. Iliopoulos, D. F. McDermott, F. J. McGovern, M. G. Harisinghani, and E. Oliva Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma N. Engl. J. Med., May 29, 2008; 358(22): 2389 - 2396. [Full Text] [PDF]
|
|
|
|
|
|
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Rathmell, W. M. Stadler, and B. I. Rini Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Klatte, D. B. Seligson, S. B. Riggs, J. T. Leppert, M. K. Berkman, M. D. Kleid, H. Yu, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7388 - 7393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma J. Clin. Oncol., October 20, 2007; 25(30): 4757 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. McDermott and M. B. Atkins More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma J. Clin. Oncol., September 1, 2007; 25(25): 3791 - 3793. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Garcia and B. I. Rini Recent Progress in the Management of Advanced Renal Cell Carcinoma CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. McDermott Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches Blood, December 15, 2006; 108(13): 4109 - 4117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Varker, S. V. Kondadasula, M. R. Go, G. B. Lesinski, R. Ghosh-Berkebile, A. Lehman, J. P. Monk, T. Olencki, K. Kendra, and W. E. Carson III Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy. Clin. Cancer Res., October 1, 2006; 12(19): 5850 - 5858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Cesana, G. DeRaffele, S. Cohen, D. Moroziewicz, J. Mitcham, J. Stoutenburg, K. Cheung, C. Hesdorffer, S. Kim-Schulze, and H. L. Kaufman Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma J. Clin. Oncol., March 1, 2006; 24(7): 1169 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Koon and M. Atkins Autoimmunity and Immunotherapy for Cancer N. Engl. J. Med., February 16, 2006; 354(7): 758 - 760. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Schleypen, N. Baur, R. Kammerer, P. J. Nelson, K. Rohrmann, E. F. Grone, M. Hohenfellner, A. Haferkamp, H. Pohla, D. J. Schendel, et al. Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma Clin. Cancer Res., February 1, 2006; 12(3): 718 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Brouwers, O. C. Boerman, W. J.G. Oyen, and M. B. Atkins In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8886 - 8886. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Panelli, E. Wang, and F. M. Marincola The Pathway to Biomarker Discovery: Carbonic Anhydrase IX and the Prediction of Immune Responsiveness Clin. Cancer Res., May 15, 2005; 11(10): 3601 - 3603. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
